[go: up one dir, main page]

RU2015133310A3 - - Google Patents

Download PDF

Info

Publication number
RU2015133310A3
RU2015133310A3 RU2015133310A RU2015133310A RU2015133310A3 RU 2015133310 A3 RU2015133310 A3 RU 2015133310A3 RU 2015133310 A RU2015133310 A RU 2015133310A RU 2015133310 A RU2015133310 A RU 2015133310A RU 2015133310 A3 RU2015133310 A3 RU 2015133310A3
Authority
RU
Russia
Application number
RU2015133310A
Other versions
RU2669367C2 (ru
RU2015133310A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2015133310A publication Critical patent/RU2015133310A/ru
Publication of RU2015133310A3 publication Critical patent/RU2015133310A3/ru
Application granted granted Critical
Publication of RU2669367C2 publication Critical patent/RU2669367C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/50Nitrogen atoms bound to hetero atoms
    • C07D277/52Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2015133310A 2013-03-15 2014-03-13 Модуляторы натриевого канала для лечения боли RU2669367C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787618P 2013-03-15 2013-03-15
US61/787,618 2013-03-15
PCT/US2014/025809 WO2014151472A1 (en) 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain

Publications (3)

Publication Number Publication Date
RU2015133310A RU2015133310A (ru) 2017-04-20
RU2015133310A3 true RU2015133310A3 (ru) 2018-02-28
RU2669367C2 RU2669367C2 (ru) 2018-10-11

Family

ID=51580969

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015133310A RU2669367C2 (ru) 2013-03-15 2014-03-13 Модуляторы натриевого канала для лечения боли

Country Status (16)

Country Link
US (1) US10179781B2 (ru)
EP (1) EP2968234B1 (ru)
JP (1) JP6449845B2 (ru)
KR (1) KR20150131254A (ru)
CN (1) CN105188694B (ru)
AU (1) AU2014234105B2 (ru)
BR (1) BR112015022096A8 (ru)
CA (1) CA2900604A1 (ru)
ES (1) ES2687481T3 (ru)
HK (1) HK1219060A1 (ru)
IL (1) IL242564A0 (ru)
MX (1) MX363680B (ru)
MY (1) MY188139A (ru)
PH (1) PH12015501740A1 (ru)
RU (1) RU2669367C2 (ru)
WO (1) WO2014151472A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
CN104797555B (zh) 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
HK1213476A1 (zh) 2013-03-14 2016-07-08 基因泰克公司 取代的三唑並吡啶及其使用方法
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
CA2900604A1 (en) 2013-03-15 2014-09-25 Chromocell Corporation Sodium channel modulators for the treatment of pain
CN105611923B (zh) * 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
US20170304306A1 (en) * 2014-09-09 2017-10-26 Chromocell Corporation SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
PE20180575A1 (es) 2015-05-22 2018-04-04 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
BR112018006189A2 (pt) 2015-09-28 2018-10-09 Genentech Inc compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto
MX386261B (es) 2015-10-07 2025-03-18 Univ Arizona Inhibidores de sumoilacion de crmp2 y usos de los mismos
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック, インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
EP3390374B1 (en) 2015-12-18 2020-08-26 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック, インコーポレイテッド ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN112689636B (zh) 2018-09-10 2024-08-20 科研制药株式会社 新型杂原子芳香族酰胺衍生物以及含有其的药剂
EP3920930A4 (en) * 2019-02-04 2023-03-08 Simon Fraser University METHODS AND COMPOUNDS FOR INHIBITION OF INACTIVATION OF VOLTAGE-SENSITIVE SODIUM CHANNELS
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
NZ528639A (en) * 2001-03-14 2005-07-29 Gruenenthal Chemie Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
RU2006107211A (ru) * 2003-08-08 2007-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
WO2005054202A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
US7880000B2 (en) 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
AU2005266090A1 (en) * 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
MX2007004862A (es) 2004-10-29 2007-05-09 Astrazeneca Ab Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP5473334B2 (ja) 2005-12-23 2014-04-16 ジーランド ファーマ アクティーゼルスカブ 修飾リジン模倣化合物
EP2173743A2 (en) * 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
WO2009012241A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
GEP20135992B (en) 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
WO2011133729A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドPfizer Limited 化合物
ES2532356T3 (es) * 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
EP2590951B1 (en) * 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
EP2593427B1 (en) * 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
JP2014521749A (ja) 2011-08-17 2014-08-28 アムジエン・インコーポレーテツド ヘテロアリールナトリウムチャネル阻害剤
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
CA2900604A1 (en) 2013-03-15 2014-09-25 Chromocell Corporation Sodium channel modulators for the treatment of pain
PE20160434A1 (es) 2013-09-09 2016-05-25 Peloton Therapeutics Inc Eteres de arilo y sus usos
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂

Also Published As

Publication number Publication date
ES2687481T3 (es) 2018-10-25
HK1219060A1 (zh) 2017-03-24
MY188139A (en) 2021-11-23
US10179781B2 (en) 2019-01-15
IL242564A0 (en) 2016-02-29
EP2968234A1 (en) 2016-01-20
US20160046617A1 (en) 2016-02-18
PH12015501740A1 (en) 2015-10-19
MX363680B (es) 2019-03-29
KR20150131254A (ko) 2015-11-24
CA2900604A1 (en) 2014-09-25
BR112015022096A8 (pt) 2019-11-26
RU2669367C2 (ru) 2018-10-11
AU2014234105B2 (en) 2019-01-03
EP2968234B1 (en) 2018-06-27
BR112015022096A2 (pt) 2017-07-18
CN105188694B (zh) 2018-07-31
CN105188694A (zh) 2015-12-23
RU2015133310A (ru) 2017-04-20
WO2014151472A1 (en) 2014-09-25
JP6449845B2 (ja) 2019-01-09
EP2968234A4 (en) 2016-10-12
AU2014234105A1 (en) 2015-09-03
JP2016512844A (ja) 2016-05-09
MX2015011907A (es) 2016-05-16

Similar Documents

Publication Publication Date Title
BR112016010771A2 (ru)
BR112016011606A2 (ru)
BR112015007533A2 (ru)
BR102016010778A2 (ru)
BR112014017733A2 (ru)
BR112014017739A2 (ru)
BR112014019326A2 (ru)
BR112014018516A2 (ru)
BR112014020341A2 (ru)
BR112016002987A2 (ru)
RU2015133310A3 (ru)
BR112014017669A2 (ru)
BR112016009829A2 (ru)
BR112015025042A2 (ru)
BR112014021878A2 (ru)
BR112016010576A2 (ru)
BR112016011312A2 (ru)
RU2016113156A3 (ru)
BR112014019204A2 (ru)
BR112015015948A2 (ru)
BR112014017722A2 (ru)
BR112014017653A2 (ru)
BR112016013324A2 (ru)
BR112016013178A2 (ru)
BR112014018578A2 (ru)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200314